Sonoma Pharmaceuticals (NASDAQ:SNOA) Issues Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its quarterly earnings results on Tuesday. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.09, FiscalAI reports. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%. The company had revenue of $7.17 million for the quarter, compared to analysts’ expectations of $5.29 million.

Sonoma Pharmaceuticals Stock Performance

Shares of Sonoma Pharmaceuticals stock traded up $0.01 during midday trading on Tuesday, hitting $1.14. The company had a trading volume of 89,800 shares, compared to its average volume of 113,565. The stock has a market capitalization of $5.46 million, a P/E ratio of -0.93 and a beta of 1.31. The company has a 50 day moving average of $1.21 and a 200 day moving average of $1.66. Sonoma Pharmaceuticals has a 52-week low of $0.85 and a 52-week high of $3.95.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Sonoma Pharmaceuticals presently has an average rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment. The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations.